Max Robotics — Global Service Robot Directory + US Certification

About

Thomas Zeng is a molecular diagnostics researcher whose work has advanced the precision and reliability of clinical genetic testing. His primary research areas include hereditary cancer genomics, next-generation sequencing (NGS) assay development, and sample tracking technologies. Zeng’s most significant contribution is the development and clinical validation of a second-generation sequencing assay for detecting hereditary BRCA1 and BRCA2 mutations, published in 2013. This work, cited 42 times, provided a robust framework for translating NGS into routine diagnostic use, directly impacting the management of hereditary breast and ovarian cancer. He further addressed a critical bottleneck in high-throughput labs by designing unique sequence controls for sample tracking, ensuring data integrity and traceability in complex workflows. Zeng’s achievements lie in bridging the gap between cutting-edge sequencing technology and practical, clinically actionable solutions. His research not only enhances diagnostic accuracy but also strengthens the operational backbone of genomic medicine, making him a key figure in the evolution of personalized oncology.